Antiphospholipid antibodies affect human endometrial angiogenesis

Area of Science:

• Reproductive immunology
• Vascular biology
• Obstetrics and Gynecology

Background:

• Antiphospholipid antibodies (aPL) are linked to pregnancy complications like recurrent miscarriage in antiphospholipid syndrome (APS).
• Previous research shows aPL affect trophoblast cells, but their impact on decidual cells and endometrial angiogenesis is less understood.
• Angiogenesis, the formation of new blood vessels, is vital for successful placentation.

Purpose of the Study:

• To investigate the role of antiphospholipid antibodies (aPL) in human endometrial angiogenesis.
• To determine if aPL impact key molecular pathways involved in blood vessel formation within the endometrium.

Main Methods:

• In vitro assessment of aPL effects on human endometrial endothelial cell (HEEC) angiogenesis using Matrigel assays.
• Quantification of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) using ELISA and gelatin zymography, respectively.
• Evaluation of NF-κB DNA binding activity and in vivo angiogenesis in a murine model.

Main Results:

• Antiphospholipid antibodies (aPL) significantly reduced tubule formation by HEECs in vitro and decreased new vessel formation in vivo.
• aPL exposure led to a significant reduction in VEGF and MMPs production.
• NF-κB DNA binding activity was also found to be decreased by aPL.

Conclusions:

• Antiphospholipid antibodies (aPL) inhibit human endometrial angiogenesis.
• This inhibition of angiogenesis, mediated by reduced VEGF, MMPs, and NF-κB activity, offers a potential mechanism for the defective placentation observed in antiphospholipid syndrome (APS).